Regeneron and Sanofi said they will shut down part of a study exploring whether their arthritis therapy could treat certain hospitalized Covid-19 patients because the drug looked unlikely to help them
Regeneron Pharmaceuticals Inc. and Sanofi SA said Monday they will shut down part of a study exploring whether their arthritis therapy could treat certain hospitalized Covid-19 patients because the drug looked unlikely to help them.
An early look at ongoing trial results indicated the therapy, named Kevzara, wasn’t helping patients who were hospitalized with a severe form of Covid-19 but don’t require a ventilator’s assistance with breathing, the companies said.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Researchers should study how Covid-19 affects women'More research must be conducted to look into the potential impact of sex, along with other demographic factors, on Covid-19 patients,' writes former US Assistant Surgeon General Susan Blumenthal for CNNOpinion.
Leer más »
Researchers studying a common heartburn drug as treatment for Covid-19Hospitals in New York are giving Covid-19 patients heartburn medicine to see if it helps fight the virus. Preliminary results of the clinical trial of famotidine, the active ingredient in Pepcid, could come out in the next few weeks.
Leer más »